| Trial ID: | L0598 |
| Source ID: | NCT00528385
|
| Associated Drug: |
Spironolactone (Spironol) 25 Mg
|
| Title: |
Optimalization of Nephroprotection Using Agents Inhibiting Renin-Angiotensin-Aldosterone System
|
| Acronym: |
|
| Status: |
COMPLETED
|
| Study Results: |
NO
|
| Results: |
|
| Conditions: |
Chronic Kidney Disease|Proteinuria
|
| Interventions: |
DRUG: Spironolactone (Spironol) 25 mg
|
| Outcome Measures: |
Primary: Investigate the antiproteinuric effect of adding aldosterone antagonist, spironolactone to the combination therapy with angiotensin converting enzyme inhibitor and AT-1 receptor blocker in maximal recommended doses. | Secondary: Investigate the effect of the study intervention on urine excretion of N-acetyl-β-D-glucosaminidase, alfa1-microglobulin and amino-terminal propeptide of type III procollagen.
|
| Sponsor/Collaborators: |
Sponsor: Medical University of Gdansk
|
| Gender: |
ALL
|
| Age: |
ADULT
|
| Phases: |
|
| Enrollment: |
|
| Study Type: |
INTERVENTIONAL
|
| Study Designs: |
Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: NONE|Primary Purpose: TREATMENT
|
| Start Date: |
2005-03
|
| Completion Date: |
|
| Results First Posted: |
|
| Last Update Posted: |
2007-09-12
|
| Locations: |
|
| URL: |
https://clinicaltrials.gov/show/NCT00528385
|
